The molecular mechanism of adenomatous polyposis coli-binding protein EB1 in HCC
| Project/Area Number |
25430134
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor diagnostics
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
NAKANISHI Kazuaki 北海道大学, 医学(系)研究科(研究院), 客員研究員 (80374338)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOKOO Hideki 北海道大学大学院医学研究科, 消化器外科学分野Ⅰ, 助教 (70399947)
KAKISAKA Tatsuhiko 北海道大学大学院医学研究科, 消化器外科学分野Ⅰ, 特任研究助教 (40583092)
KAMIYAMA Toshiya 北海道大学大学院医学研究科, 消化器外科学分野Ⅰ, 准教授 (80322816)
TAKETOMI Akinobu 北海道大学大学院医学研究科, 消化器外科学分野Ⅰ, 教授 (70363364)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
ORIMO Tatsuya 北海道大学大学院医学研究科, 消化器外科学分野Ⅰ, 助教 (80711861)
|
|---|
| Research Collaborator |
FUKUHARA Takasuke
OHATA Takanori
TAKAHASHI Hidenori
KOBAYASHI Nozomi
MIYOSHI Sayaka
HORIGOME Masatoshi
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | EB1 / 肝細胞癌 / バイオマーカー / 増殖 / 浸潤 / Dlk-1 / 予後予測因子 / 再発予測因子 / Dlk1 / 再発 / 悪性度バイオマーカー |
|---|
| Outline of Final Research Achievements |
We previously reported that adenomatous polyposis coli-binding protein EB1 (EB1) is overexpressed in HCC tissues by proteomics. In present study, ①EB1 expression significantly correlated with the degree of histological differentiation, AFP, vascular invasion status in HCC patients. Moreover, overall survival and recurrence rate was significantly poor in EB1-high expressed HCC patients. ②EB1 promoted cell proliferation, migration, invasion, tumor growth in HCC cell lines. ③Microarray analysis revealed that EB1 might regulate the expression level of Dlk-1. As a conclusion, EB1 may become a new biomarker of HCC and a potential molecular target of HCC therapy.
|
Report
(4 results)
Research Products
(3 results)
